[Effective out-patient treatment of gastric ulcer with proglumide: preliminary results (author's transl)].
In a double-blind trial 16 persons with gastric ulcer and 35 with duodenal ulcer were treated as out-patients with 1200 mg proglumide daily or 1320 mg magnesium tricilicate daily (as an "active placebo") for four weeks. The ulcers were assessed by endoscopy before and after treatment. The gastric ulcers disappeared in 75% of patients receiving proglumide (six of eight subjects) but in only 25% of those on the placebo (two of eight). There was no significant effect of proglumide on duodenal ulcers (17 in the proglumide and 18 in the placebo groups). Proglumide failed to affect either basal or maximally stimulated acid secretion, nor was there any change in the serum gastrin level. There were no side effects during proglumide administration. This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone.
D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D005745:Gastric Acidity Determination; D005755:Gastrins / Q000097:blood; D005773:Gastroscopy; D005973:Glutamine / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011377:Proglumide / Q000627:therapeutic use*; D013276:Stomach Ulcer / Q000175:diagnosis / Q000188:drug therapy*
D005755:Gastrins; D010919:Placebos; D005973:Glutamine; D011377:Proglumide
Wirksame ambulante Therapie des Ulcus ventriculi mit Proglumid. Vorläufige Mitteilung.